Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: Analysis of HemoRec registry data from the Czech Republic

Haemophilia

Volumn 15, Issue 3, 2009, Pages 752-759

  Salaj, Peter ^a   Brabec, P ^b   Penka, M ^c   Pohlreichova, V ^a   Smejkal, P ^c   Cetkovsky, P ^a   Dusek, L ^b   Hedner, U ^d  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Bleeding; Dose; Haemophilia; Inhibitors; Registry; RFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; CLINICAL ARTICLE; CZECH REPUBLIC; DATA ANALYSIS; DATA COLLECTION METHOD; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HUMAN; INCIDENCE; MUSCLE BLEEDING; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; REGISTER; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; THROMBOEMBOLISM;

ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CZECH REPUBLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; HEMARTHROSIS; HEMOPHILIA A; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449145067     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02007.x     Document Type: Article

References (30)

1. Haya S, Moret A, Cid AR et al. Inhibitors in haemophilia A: Current management and open issues. Haemophilia 2007; 13: 52-60.
2. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-31.
3. Morfini M, Haya G, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
4. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. J Thromb Haemost 1998; 80: 773-8.
5. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. J Thromb Haemost 1998; 80: 912-8.
6. -1 -dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia 2008; 14: 287-94.
7. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial. N Engl J Med 1980; 21: 421-5.
8. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 24: 717-21.
9. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
10. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. J Thromb Haemost 1999; 82: 531-9.
11. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
12. Kavakli K, Makris M, Zulfikar B et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
13. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
14. HemoRec registry web site. Available at: http://www.hemorec.com (last accessed on 3 October 2008).
15. Furie B, Limentani SA, Rosenfield CG. A practical guide to the evaluation and treatment of hemophilia. Blood 1994; 84: 3-9.
16. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing treatment for haemophilia patients with inhibitors using thromboelastography. Haemophilia 2006; 12: 598-604.
17. Abshire TC. Dose optimisation of recombinant activated factor VII for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing. Semin Hematol 2004; 41: 3-7.
18. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R. Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
19. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-57.
20. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-55.
21. Roosendaal G, Vianen ME, Marx JJ, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: A human in vitro study. Arthritis Rheum 1999; 42: 1025-32.
22. Sherry DD. Avoiding the impact of musculoskeletal pain on quality of life in children with hemophilia. Orthop Nurs 2008; 27: 103-8.
23. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young haemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven ®). J Thromb Haemost 2003; 1: 450-5.
24. Kenet G, Lubetsky A, Luboshitz J, Gitel S, Varon D, Martinowitz U. Treatment of inhibitor patients with rFVIIa: Continuous infusion protocols as compared to single, large dose. Haemophilia 2000; 6: 279.
25. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
26. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 1999; 104: 22-6.
27. Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: A review of the literature. Haemophilia 2007; 14: 233-41.
28. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
29. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven ®) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S55-68.
30. Acharya SS, Coughlin A, Dimichele DM; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorders Registry: Deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2: 248-56.